The research described pooled results from two phase III trials evaluating the safety and efficacy of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin in non-small cell lung cancer (NSCLC) patients with brain metastases.
“These data demonstrate that Xcytrin, used in combination with whole brain radiation therapy, may significantly improve neurologic outcomes in patients with brain metastases from non-small cell lung cancer,” said William Shapiro, chief of the neuro-oncology division of neurology at the Barrow Neurological Institute.
“We are moving forward with preparation of a new drug application with the FDA and anticipate filing by the end of the calendar year,” said Richard Miller, president and CEO of Pharmacyclics.